Alerta

DATA VISUALIZATION FOR CONTINUOUS GLUCOSE MONITORING

Resumen de: WO2026009101A1

A method for continuous glucose monitoring includes a processor of a computing device operatively coupled to or integrated with a display receiving data. The data includes a plurality of glucose levels, and each glucose level of the plurality of glucose levels is associated with a corresponding time. The processor processes the data to generate a first graphical element indicative of a current glucose level, and one or more second graphical elements indicative of a rate and a direction of change of the glucose level. The processor via a graphical user interface displays the first graphical element on the display and the one or more second graphical elements on the display. The one or more second graphical elements are positioned relative to the first graphical element to visually indicate whether the glucose level is stable, increasing, or decreasing.

WRIST-WORN BLOOD GLUCOSE MONITORING DEVICE

Resumen de: WO2026010518A1

The aim of the invention is to provide for virtually continuous monitoring of a person's blood glucose level in the case of the occurrence and repair of a fault in a wrist-worn blood glucose monitoring device caused by the breakage of wires or failure of a sensor which are located in a section of a strap or wristband by permitting expeditious replacement of the section containing the sensor and wires. The technical results of the invention include: permitting expeditious repair of a wire breakage or sensor failure-related fault in the device by replacement of a section of the strap or wristband, wherein the time required to replace the section of the strap or wristband is not greater than the interval between blood glucose level measurements; permitting the use of the body of the device with strap or wristband sections of different lengths; and permitting expeditious replacement of sections of the strap or wristband of the device if the wearer has an allergic reaction to the material of the sections of the strap or wristband.

METHODS TO RAPIDLY ASSESS CHANGES IN MEDICAMENT NEEDS FOR ACCELERATED SHORT-TERM ADAPTIVITY OF AUTOMATED MEDICAMENT DELIVERY SYSTEMS

Resumen de: US20260007824A1

Exemplary embodiments relate to automated medicament delivery (AMD) devices. Exemplary methods and apparatuses allow the AMD to account for the eventual impact of remaining medicament-on-board (MOB) on reduction in glucose concentrations, and do not incorporate the impact of meals on increases in glucose concentrations. This allows the AMD system to estimate the user's final glucose concentration if the impact of both carbohydrate ingestion and existing MOB are fully realized. Consequently, an AMD system can personalize its behaviors to a particular user more rapidly than if the system were to rely simply on previous medicament delivery and glucose histories. This is especially useful when a user begins using an AMD system with an inaccurate or poorly estimated initial value for total daily medicament (TDM) delivery.

APPARATUS AND METHOD FOR NON-INVASIVE BLOOD GLUCOSE MONITORING

Resumen de: US20260007335A1

The present invention relates to apparatus for non-invasive blood glucose monitoring, which includes: a signal transmitting module that transmits a terahertz wireless signal modulated into a PRBS pattern at a terahertz carrier frequency to a body part; a signal receiving module that demodulates the terahertz wireless signal reflected from the body part to measure performance parameters of the modulation pattern; and a sensing module that performs multivariate analysis using the performance parameters of the modulation pattern measured through the signal receiving module and quantifies features related to blood glucose through the multivariate analysis to measure blood glucose concentration.

METHOD, SYSTEM AND COMPUTER READABLE MEDIUM FOR ASSESSING ACTIONABLE GLYCEMIC RISK

Resumen de: US20260007370A1

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.

THERMAL IMAGING SYSTEM FOR DETECTION OF EARLY STAGES OF DIABETIC FOOT ULCERS

Resumen de: US20260007359A1

A thermal imaging system for detection of diabetic foot ulcers including a mobile device having a graphical user interface. The thermal imaging system includes a thermal camera in communication with the mobile device for obtaining thermal images of patient feet and sending the thermal images to the mobile device. The thermal imaging system includes an application on the mobile device having instruction for analyzing the thermal images using a temperature condition index during analysis. The application provides data results on the interactive dashboard of the graphical user interface. The instruction for analyzing the thermal images include AI-driven analysis for delivering rapid results, reducing need for extensive medical expertise. Following analysis, the application generates a detailed report including information on categorization of the diabetic foot condition, risk level, recommended screening frequency and suggested actions.

SYSTEMS, METHODS, AND DEVICES FOR BIOPHYSICAL MODELING AND RESPONSE PREDICTION

Resumen de: US20260007336A1

Various systems and methods are disclosed. One or more of the methods disclosed uses machine learning algorithms to predict biophysical responses from biophysical data, such as heart rate monitor data, food logs, or glucose measurements. Biophysical responses may include behavioral responses. Additional systems and methods extract nutritional information from food items by parsing strings containing names of food items.

GLUCOSE SENSOR APPARATUS ADDRESSING INTERFERENCE OF ASCORBIC ACID AND ACETAMINOPHEN

Resumen de: US20260007341A1

This disclosure relates to an apparatus for glucose-sensing that address interference of ascorbic acid and acetaminophen. The apparatus includes a first electrode capable of oxidizing glucose and at least one of ascorbic acid and acetaminophen. The apparatus further includes a second electrode capable of oxidizing at least one of ascorbic acid and acetaminophen but not capable of oxidizing glucose. The first electrode includes a deposit of irregularly shaped bodies that are formed of numerous nanoparticles having a generally oval or spherical shape with a length ranging between about 2 nm and about 5 nm.

DETERMINATION OF STRESS-RELATED CONTRIBUTIONS TO BLOOD GLUCOSE LEVEL

Resumen de: WO2026008357A1

In an approach to determining stress contributions to blood glucose levels, the present invention receives a blood glucose signal over a first period of time and a biomarker signal over a second period of time. The present invention extracts one or more blood glucose level signal features from the blood glucose signal, one or more biomarker signal features from the biomarker signal to determine a blood glucose level of time-based stress contribution and a biomarker-based stress contribution.

ESTIMATION OF DIABETES RISK BASED ON BIOMARKERS

Resumen de: WO2026008382A1

In an approach to estimating diabetes risk, the present invention receives a biomarker signal over a first period of time. From the biomarker signal, the presently claimed invention extracts one or more features of the biomarker signal and determines a first trend associated with insulin resistance based on the one or more features of the biomarker signal. Using this information, the present invention can determine a relative non-digestion-related contribution to the blood glucose signal and/or a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion- related contribution is determined from the relative digestion-related and non-digestion-related contribution.

DISAGGREGATION OF FACTORS AFFECTING BLOOD GLUCOSE LEVEL

Resumen de: WO2026008380A1

In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time. The present invention further contemplates the extraction of one or more features of the blood glucose signal received from the one or more sensors. Using this information, a relative non-digestion- related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion- related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.

BLOOD GLUCOSE LEVEL DISAGGREGATION BASED ON BIOMARKERS

Resumen de: WO2026008436A1

In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time and a biomarker signal from one or more sensors over an overlapping period of time. The present invention further contemplates the extraction of one or more features of the biomarker signal received from the one or more sensors. Using this information, a relative non-digestion-related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.

BLOOD GLUCOSE LEVEL SENSING DEVICE

Resumen de: WO2026008858A1

A blood glucose level sensing device for non-invasive blood glucose level measurement of a subject is disclosed. The device comprises: a digit-depth unit configured to measure or receive a depth of a digit of the subject; a measurement light generation element configured to direct measurement light through the digit; and a light-transmission measurement unit configured to measure a transmission index representing the proportion of the measurement light transmitted through the digit. The device also has a digit characteristic parameter unit configured to receive one or more digit characteristic parameters indicative of: a skin tone of the digit; a nail texture of the digit; a nail thickness of the digit; a nail length of the digit; and a nail polish status of the digit. The device is configured to determine a blood glucose level measurement based on the transmission index, the depth of the digit and at least one of the digit characteristic parameters. Also disclosed is a method of non-invasively determining a blood glucose level of a subject via a digit of the subject.

AUTOMATIC MONITORING METHOD BASED ON RATE OF CHANGE OF DIFFERENCE BETWEEN ACTUAL BLOOD GLUCOSE VALUES, AND CLOSED-LOOP ARTIFICIAL PANCREAS

Resumen de: EP4675641A1

The invention discloses an automatic detection method based on the change rate of the difference between the actual blood glucose values, including: obtaining an actual blood glucose value of the user at the current time; obtaining a historical actual blood glucose value of the user at the previous time, and calculate a difference between the actual blood glucose values at the current time and at the previous time; calculating a change rate of the difference between the actual blood glucose values at the current time; and comparing the change rate of the difference between the actual blood glucose values at the current time with a preset threshold, and determining an event type according to the comparing result. According to the determined event type, the artificial pancreas can automatically adjust the corresponding infusion strategy to achieve closed-loop control of the artificial pancreas.

BLOOD GLUCOSE STATES BASED ON SENSED BRAIN ACTIVITY

Resumen de: US2024315611A1

Blood glucose states based at least on sensed brain activity data. Blood glucose states may be predicted states using prediction models, and may be real-time or future glucose states. One or more wearable sensors, optionally adapted for use in either single channel or dual channel sensing, can record brain activity signals and communicate brain activity signal data to a remote device.

Discovering and annotating segments of physiological data corresponding to changes in disease state

Resumen de: US12514515B1

Introduced here are diabetes management platforms able to make annotations to physiological data of a subject whose glycemic health state is being monitored. These annotations can be used to classify excursions detected in the physiological data to facilitate the identification of a therapeutic behavior change intended to improve the glycemic health state of the subject. For example, a health coach may review the annotation(s) associated with the subject before generating a recommendation for improving the glycemic health state. As another example, the diabetes management platform can automatically identify an appropriate recommendation based on the annotation(s).

BLOOD GLUCOSE AND BLOOD OXYGEN MULTI-PARAMETER DETECTION CHIP AND WEARABLE DEVICE

Resumen de: WO2026001285A1

The present application provides a blood glucose and blood oxygen multi-parameter detection chip and a wearable device. The present application relates to the technical field of semiconductors. The multi-parameter detection chip comprises a coupler, a gating device, and a plurality of outlets that are optically connected in sequence and integrated together, as well as a light source capable of emitting light of different wavelengths and a detector. The coupler is configured for coupling the light of different wavelengths emitted by the light source to the gating device. The gating device selects the light of different wavelengths and allows the light to enter the corresponding outlets so that the light exits by means of the outlets. The detector is configured for receiving the light that exits by means of the outlets and is then reflected or transmitted back. Arranging an array of outlets and replacing traditional point detection with plane detection can greatly improve the detection accuracy. In addition, the wavelength coverage of the blood glucose and blood oxygen multi-parameter detection chip spans the entire visible to near-infrared light waveband, so that the chip can perform multi-wavelength detection, thereby enabling multi-parameter measurement.

METHOD FOR DETERMINING A SUBSTANCE CONCENTRATION AND DETECTOR ARRANGEMENT

Resumen de: WO2026002585A1

The invention concerns a method for determining a substance concentration in a sample comprising liquid containing particles, in particular glucose in blood, wherein a refractive index of the liquid is dependent on a concentration of the substance dissolved therein and a density of particles in the liquid is substantially constant, wherein the liquid is modulated in its volume or pressure. The proposed method obtains a first signal during a first time period with an acquisition rate that is at least two times larger than a periodicity of the volume or pressure modulation of the liquid and determines a variability therefrom. The variability or its change thereof over time directly corresponds to the concentration of the substance or a change thereof.

DYNAMIC MEASUREMENT OF CONSTITUENT CONCENTRATION IN AQUEOUS SOLUTIONS

Resumen de: WO2026006322A1

Constituents of a liquid, such as blood, may exhibit optical signatures that allow for real-time, dynamic concentration detection. For example, concentrations of substances in aqueous solutions, including calcium, potassium, sodium, bicarbonate, chloride, magnesium, phosphate, lactate, acetate, glucose, creatinine, urea, and/or hydrogen peroxide, may be monitored during dialysis or other treatments. This is achieved by measuring real-time changes in light intensity at wavelengths corresponding to the constituents' optical signatures. Concentration may be determined using a predetermined relationship between light intensity and concentration at isolated wavelengths. Real-time monitoring enables timely treatment adjustments, improving patient outcomes.

PREVENTING YELLOWING AND FLUORESCENCE IN EPOXIDE DIAMINE NETWORKS

Resumen de: WO2026005935A1

An encasement material that resists degradation, including yellowing. The encasement material may be used, for example, in an apparatus including a housing, circuitry at least partially within the housing, that is implanted into an animal (e.g. a human) to continuously monitor the concentrations of specific analytes, such as glucose. The encasement material allows for the efficient transmission of excitation and emission light to and from an analyte indicator in the device. The encasement material includes additives that resist and inhibit degradation of the encasement material thereby improving the longevity and life of the device. Also, methods for forming the encasement material and incorporating the encasement material within an apparatus.

GASTROINTESTINAL ELECTRICAL SIGNAL-BASED DIABETES AND HYPERTENSION PREDICTION SYSTEM AND CONSTRUCTION METHOD

Resumen de: WO2026000747A1

The present invention relates to the field of disease prediction, and in particular, to a gastrointestinal electrical signal-based diabetes and hypertension prediction system and a construction method. The prediction system provided by the present invention comprises: a database, used for storing gastrointestinal electrical signal data, comprising the postprandial coupling percentage at the lesser curvature lead, the postprandial electrical dysrhythmia percentage at the gastric antrum lead, the preprandial dominant frequency at the lesser curvature lead, the postprandial average waveform frequency at the ascending colon lead, the postprandial normal slow wave percentage at the ascending colon lead, the postprandial coupling percentage at the descending colon lead, the postprandial average waveform frequency at the rectal lead, the preprandial average waveform frequency at the transverse colon lead, and the preprandial lead time difference at the rectal lead; and a prediction module, used for predicting a probability of the occurrence of diabetes and hypertension in a subject. Further provided in the present invention is a construction method for the prediction system. The present invention is adapted to performing diabetes and hypertension risk prediction and screening work in rural or community populations.

SERVER FOR PREDICTING DETERMINATION ON DIABETIC FOOT ON BASIS OF PLURALITY OF PIECES OF DATA ON BASIS OF PREDICTION MODEL, AND DRIVING METHOD THEREFOR

Resumen de: WO2026005140A1

According to various embodiments, a server for predicting determination on a diabetic foot on the basis of a plurality of pieces of data on the basis of a prediction model, comprises: a communication interface; a memory; and a processor, wherein the processor is configured to: obtain at least one piece of image data and at least one piece of first sensing data from an external server of an external user through the communication interface; obtain first ulcer output data by inputting the at least one piece of image data and the at least one piece of first sensing data to the prediction model; when it is determined that the first ulcer output data exceeds a preset first threshold value on the basis of a result of comparing the first ulcer output data with the preset first threshold value, output that a foot ulcer of the external user is likely to be diabetic foot ulcer; when it is determined that the first ulcer output data exceeds a second threshold value set to be greater than the first threshold value on the basis of a result of comparing the first ulcer output data with the second threshold value, output that the foot ulcer of the external user is highly likely to be the diabetic foot ulcer; and transmit, through the communication interface, result data for the first ulcer output data determined to exceed the first threshold value and/or the second threshold value, and guideline data presenting at least one guideline on the basis of the result data, wherein the prediction m

NEUROMODULATION SYSTEM TO INDUCE CHANGES IN GLYCEMIC REGULATORY SYSTEM PLASTICITY

Resumen de: US20260000895A1

Current Type 2 Diabetes Mellitus treatments include life-style management, pharmaceuticals and may include bariatric surgery for the morbidly obese. However, issues with compliance, side effects and permanent anatomical alterations provide a need for an alternative therapy to modulate a peripheral nerve, such as the vagus nerve, in a manner that causes a plastic change in the glycemic regulatory system, with or without the involvement of the central nervous system (CNS), that changes the activity of an organ and thereby changing the activity of that organ. Low energy vagus nerve neuromodulation has potential as a new treatment for type 2 diabetes mellitus by inducing plasticity of the body's glycemic regulatory system with low energy transient stimulation. This will allow for effective use of a small implantable pulse generator that requires infrequent, or no, charging during the life of the device.

Protable device and method for non-invasive measurement of the level of physiological values sPortable device and method for non-invasive estimation of the level of

Resumen de: US20260000363A1

A portable device and method for non-invasive estimation of the level of physiological values such as blood glucose and blood cholesterol, comprising a central processing unit (1) which includes connections to: a signal emitter which emits signals via electrodes in contact with the skin, which, when processed by a bioimpedance microcontroller and said central processing unit (1), provide values such as hydration, body mass index, bone index; a digital optical sensor (4) which allows calculation of the blood oxygen value, heart rate and temperature; and enzymatic sensors (5) which determine the quantity of glucose or lactate; said central processing unit (1) calculating the physiological values on the basis of an automatic learning algorithm that has been trained with a set of clinical history data from a group of patients for whom at least values of bioimpedance, temperature, oxygen and heart rate are available.

SELF-INSERTING TROCARLESS ANALYTE-SENSING CANNULA

Nº publicación: US20260000831A1 01/01/2026

Solicitante:

PACIFIC DIABETES TECH INC [US]
Pacific Diabetes Technologies Inc

Resumen de: US20260000831A1

The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.